Find information on thousands of medical conditions and prescription drugs.

Tolterodine

Tolterodine (ATC code: G04BD) is an antimuscarinic drug that is used to treat urinary incontinence. It is sold under the trade name Detrol. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas most antimuscarinic treatments for overactive bladder only act on M3 receptors making them more selective. Tolterodine, however, although it acts on two types of receptors, has less side effects than other antimuscarinics eg. oxybutynin (which is selective for M3 only) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are less side effects eg. hyposalivation, constipation, decreased gastric motility.

Read more at Wikipedia.org


[List your site here Free!]


Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive ... : An article from: Mayo Clinic Proceedings $20.00 Once-daily tolterodine for overactive bladder. (Convenient, Well Tolerated). : An article from: Internal Medicine News $5.95
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results ... : An article from: Mayo Clinic Proceedings $20.00

Once-daily Tolterodine treats overactive bladder: More effective than twice-daily version
CHICAGO -- Once-daily tolterodine 4 mg is an effective, well tolerated, and convenient therapy for overactive bladder in women, two investigators said ...
Is tolterodine or oxybutynin the best for treatment of urge urinary incontinence? - Detrol - Ditropan - POEMs
Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001; ...
Is extended-release oxybutynin or tolterodine more effective in the treatment of an overactive bladder? - Ditropan XL - Detrol
Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of t
Tolterodine Safe, Effective When Taken Over a 2-Year Period
HILTON HEAD ISLAND, S.C. -- Tolterodine tartrate given at a dosage of 2 mg twice daily for the treatment of overactive bladder maintains its efficacy ...
ACOG guidelines on urinary incontinence in women
The American College of Obstetricians and Gynecologists (ACOG) has released recommendations on the diagnosis and treatment of urinary incontinence in ...
Ranbaxy Receives Tentative Approval to Market Tolterodine Tartrate Tablets
PRINCETON, N.J., Sept. 16 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced ...
Selecting medications for the treatment of urinary incontinence
In response to the growing population of older patients with incontinence, pharmaceutical companies are developing new drugs to treat the condition. Before prescribing medications for incontinence,
Clinical quiz
Clinical Quiz questions are based on selected articles in this issue of American Family Physician. Answers appear in this issue. AFP has been reviewed ...

Home Contact Resources Exchange Links ebay